Eggermont et al (1996b,c) reported that in patients with advanced STS an ILP with TNF + melphalan with Interferon-gamma or without interferon-gamma improved tumour response rates to above 80% resulting in a limb salvage in over 70% of the patients destined otherwise to undergo an amputation. The results of the multicenter studies in Europe eventually lead to the approval of TNF for this indication in Europe (Eggermont et al, 1999). This evidence concerns the gene IFNG and telomere syndrome.